跳至主要内容
临床试验/KCT0001257
KCT0001257尚未招募未知

Korean Alzheimer’s Disease Neuroimaging Initiative

Asan Medical Center0 个研究点目标入组 500 人开始时间: 待定最近更新:
适应症

试验速览

阶段
未知
状态
尚未招募
入组人数
500

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational Study

入排标准

年龄范围
50(Year) 至 80(Year)(—)
性别
All

入选标准

  • The inclusion criteria for this study are as follows
  • 1) Common criteria
  • ?Age between 50 and 80 years old on the first day of the baseline visit.
  • ?At least 6 years of education, and literate.
  • ?Visual and auditory acuity adequate for neuropsychological testing.
  • ?Geriatric Depression Scale less than 6 and no evidence of depression.
  • ?Willing to undergo repeated Magnetic Resonance Imaging (MRI) and at least 2 Positron Emission Tomography (PET) scans and no medical contraindications to MRI
  • ?Agrees to lumbar puncture and neuropsychological testing
  • Visiting with a study partner who has frequent contact with the subject (e.g. an average of 2 hours per day or more), and can accompany the subject to all clinic visits for the duration of the protocol is recommended.
  • ?NO significant change in medication within 3 months of screening.
  • 2) Cognitively normal (CN)
  • ?Satisfies common criteria
  • ?Free of memory complaints..
  • ?Delayed recall subscores of the Seoul Verbal Learning Test, controlled for level of education and age, above -1.0 SD(Standard Deviation)
  • ?Mini Mental Status Examination(K-MMSE) score controlled for level of education and age, above -1.5 SD(Standard Deviation)
  • ?Clinical Dementia Rating scale(CDR) and memory box score both 0.
  • ?Cognitively normal based on an absence of significant impairment in cognitive functions or activities of daily living.
  • 3) Mild cognitive impairment (MCI)
  • ?Satisfies common criteria
  • ?Subjective memory concern reported by subject and caregiver
  • ?Delayed recall subscores of the Seoul Verbal Learning Test, controlled for level of education and age, below -1.0 SD(Standard Deviation). (Early MCI: -1.5 ~ -1.0 SD(Standard Deviation), Late MCI: < -1.5 SD(Standard Deviation))
  • ?Mini Mental Status Examination(K-MMSE)score controlled for level of education and age, above -1.5 SD(Standard Deviation).
  • ?Clinical Dementia Rating scale(CDR) and memory box score both 0.5.
  • ?Absence of significant impairment in activities of daily living.
  • 4) Alzheimer’s disease (AD)
  • ?Satisfies common criteria
  • ?Subjective and objective memory concern reported by subject and caregiver .
  • ?Delayed recall subscores of the Seoul Verbal Learning Test, controlled for level of education and age, below -1.5 SD(Standard Deviation).
  • ?Mini Mental Status Examination(K-MMSE)score controlled for level of education and age, below -1.0 SD(Standard Deviation).
  • ?Clinical Dementia Rating scale(CDR) 0.5 or 1.
  • ?Probable AD by the National Institute of Neurological and Communicative Disorders and Stroke / the Alzheimer's disease and related Disorders Association (NINCDS/ADRDA) criteria.
  • 5) Subcortical Ischemic Vascular Dementia (SIVD)
  • ?Satisfies common criteria.
  • ?All of the following
  • A. At least 2 of the following vascular risk factors within 5 years
  • - Hypertension, Diabetes, hyperlipidemia, smoking, obesity (Body Mass Index, BMI > 25.0)
  • B. Documented history of more than 1 focal neurologic symptom, sign
  • C. White matter hyperintensities, above moderate severity, on MRI images
  • ?Delayed recall subscores of the Seoul Verbal Learning Test, controlled for level of education and age, below -1.5 SD(Standard Deviation).
  • ?Mini Mental Status Examination(K-MMSE)score controlled for level of education and age, below -1.0 SD(Standard Deviation).
  • ?Clinical Dementia Rating scale(CDR) 0.5 or 1.

排除标准

  • ?Previous or current diagnosis of:
  • A.Major neurodegenerative disease such as Parkinson’s disease
  • B.Vascular dementias not included in the diagnostic categories, such as multi-infarct dementia, strategic-infarct dementia
  • C.Brain lesions with focal neurologic deficits. (e.g., Huntington’s disease, Normal pressure hydrocepalus, Brain tumor, Progressive supranuclear palsy)
  • D.Seizure disorders that may cause generalized tonic-clonic seizures
  • E.Diseases or disorders that may cause secondary cognitive impairment
  • ?Subjects wiith focal lesions suggestive of infection or infarction on brain MRI. Subjects with < 5 lacunae may participate
  • ?Major psychiatric disorder, such as schizophrenia, major depressive disorder or bipolar disorder within the past 2 years
  • ?Uncontrolled sleeping, anxiety or behavioral disorder within 3 months
  • ?Alcohol or substance dependence within the past 2 years
  • ?Any significant systemic illness or unstable medical condition which could lead to difficulty complying with the protocol.
  • F.Malignant tumor within the past 3 years. Subjects with curable tumors and thyroid cancer, as well as other mild tumors the investigator deems mild may participate. Subjects in remission may also participate.
  • G.Medical illnesses that may cause psychiatric disorders. To be considered on a case-by-case basis at the discretion of the investigator.
  • ?Current use of specific psychoactive medications (e.g., certain antidepressants, neuroleptics, chronic anxiolytics or sedative hypnotics, etc.).
  • ?Subject is not pregnant, lactating, or of childbearing potential (i.e. women must be two years post-menopausal or surgically sterile).
  • ?Investigational agents are prohibited one month prior to entry and for the duration of the trial.
  • ?Subject unable for PET scan. This may include, but is not limited to the following:
  • A.Claustrophobic, subjects unable to maintain supine position for more than 40 minutes.
  • B.Previous adverse event to 18F-flutemetamol or related substances such as polysorbate 80

研究者

相似试验